Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immune Response of HSV Vaccine in Healthy Participants
NCT04762511Phase 1Terminated
- Sponsor
- GSK
- Start
- Mar 2021
- Primary completion
- May 2021
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, single-blind trial of GSK4108771A in herpes simplex virus type 2 infection (8 arms), sponsored by GSK. Primary endpoints: Percentage of participants reporting solicited administration site events, Percentage of participants reporting solicited systemic events and 6 more. Started Mar 2021; status: terminated.
02
Drugs
GSK4108771A
03
Conditions
herpes simplex virus type 2 infection
Beyond the preview
Go deeper on NCT04762511.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04762511.